心舒2号治疗慢性心力衰竭的临床研究

目的观察心舒2号对慢性心力衰竭(chornic heart failure,CFH)患者血浆N末端脑钠肽原((N-terminal-proBNP,NT-proBNP)水平的影响及临床疗效。方法选取不同程度慢性心力衰竭患者70例,随机均分为治疗组(n=35)和对照组(n=35),2组均以心力衰竭治疗指南为常规治疗,治疗组在常规治疗基础上口服心舒2号。治疗前及治疗后4周检测左室射血分数(LVEF%)、NT-proBNP。结果治疗组有效率94.28%,对照组有效率71.42%,2组差异有统计学意义。治疗后,治疗组LVEF%为(59.38±6.56)%,NT-proBNP为(1564.6±248.5)ng/L,对照组上述指标分别为(47.32±5.43)%,(698.5±126.8)ng/L,治疗后2组LVEF升高、NT-proBNP水平下降,但治疗组更显著(P<0.05),2组差异有统计学意义。结论心舒2号配合西药常规治疗慢性心衰疗效显著,值得临床推广。

Objective To observe the effects of XiShu2 on N-terminal pro-B-type natriuretic peptide （NT-proBNP）in patients with chronic heart failure and the clinical therapeutic effect.Method A total of 70 patients with CHF, who had already received conventional therapy, were randomly divided into two groups： the treatment group （n=35） and the control group （n=35）. The patients in the treatment group were treated with XiShu2 on the base of routine therapy. NT-proBNP levels and left ventricular function were analyzed before and 4 weeks after treatment.Results The total efifcacy of cardiac function was 94.28% in the treatment group and 71.42% in the control group after treatment （P〈0.05）. After treatment, LVEF% and NT-proBNP in the treatment group respectively were （59.38±6.56）% and （1564.6±248.5）ng/L, in the control group were （47.32±5.43）% and （698.5±126.8）ng/L. NT-proBNP was reduced, while left ventricular function was enhanced . Compared with the control group, the treatment group show signiifcant difference （P〈0.05）.Conclusion XiShu2 combined with the conventional therapy is an effective therapy to CHF.